Neutralization of Human Immunodeficiency Virus Type 1 by Complement Occurs by Viral Lysis

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1990 Dec 1

PMID 1700828

Citations 31

Authors

G T Spear

B L Sullivan

A L Landay

T F Lint

Affiliations

Soon will be listed here.

Abstract

The ability of complement to inactivate human immunodeficiency virus (HIV) in the presence of specific antibody was evaluated. HIV was treated with complement and/or antibody, and then its titer was determined on the CD4+ H9 cell line. While complement alone had no effect on the HIV titer, complement plus subneutralizing levels of antibody resulted in titer reductions. Complement sources deficient in membrane attack component C5 or C8 did not inactivate antibody-treated HIV, suggesting that neutralization occurred via lysis. This possibility was investigated by assessing release of reverse transcriptase (RT) from the virion. Antibody plus complement, but neither reagent alone, released RT from HIV in a dose-dependent manner. Release of RT did not occur with C5- or C8-deficient sera, also indicating a requirement for membrane attack components. These studies show that complement can neutralize HIV via the classical complement pathway and that this neutralization occurs via C5b-9-mediated viral lysis. Thus, complement may play a major role in resistance to disease by lysing HIV and preventing infection of Fc- and complement receptor-positive cells, as well as CD4+ cells.

Citing Articles

Nanobody-mediated complement activation to kill HIV-infected cells.

Pedersen M, Pedersen D, Winkler M, Olesen H, Sogaard O, Ostergaard L EMBO Mol Med. 2023; 15(4):e16422.

PMID: 36799046 PMC: 10086584. DOI: 10.15252/emmm.202216422.

Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.

Dufloo J, Guivel-Benhassine F, Buchrieser J, Lorin V, Grzelak L, Dupouy E EMBO Rep. 2019; 21(2):e49351.

PMID: 31833228 PMC: 10563447. DOI: 10.15252/embr.201949351.

Complement in malaria immunity and vaccines.

Kurtovic L, Boyle M, Opi D, Kennedy A, Tham W, Reiling L Immunol Rev. 2019; 293(1):38-56.

PMID: 31556468 PMC: 6972673. DOI: 10.1111/imr.12802.

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.

Zolla-Pazner S, Alvarez R, Kong X, Weiss S Curr Opin HIV AIDS. 2019; 14(4):309-317.

PMID: 30994501 PMC: 6542703. DOI: 10.1097/COH.0000000000000551.

Active Human Complement Reduces the Zika Virus Load via Formation of the Membrane-Attack Complex.

Schiela B, Bernklau S, Malekshahi Z, Deutschmann D, Koske I, Banki Z Front Immunol. 2018; 9:2177.

PMID: 30386325 PMC: 6199351. DOI: 10.3389/fimmu.2018.02177.

References

Homsy J, Meyer M, Tateno M, Clarkson S, Levy J . The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science. 1989; 244(4910):1357-60. DOI: 10.1126/science.2786647. View

Lin R, Wildfeuer O, Franklin M, Candido K . Hypocomplementemia and human immunodeficiency virus infection. Clinical correlates and relationships to circulating immune complex and immunoglobulin G levels. Int Arch Allergy Appl Immunol. 1988; 87(1):40-6. DOI: 10.1159/000234646. View

Perricone R, Fontana L, De Carolis C, Carini C, Sirianni M, Aiuti F . Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS). Clin Exp Immunol. 1987; 70(3):500-7. PMC: 1542193. View

Banapour B, Sernatinger J, Levy J . The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology. 1986; 152(1):268-71. DOI: 10.1016/0042-6822(86)90392-2. View

Takeda A, Tuazon C, Ennis F . Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science. 1988; 242(4878):580-3. DOI: 10.1126/science.2972065. View

Tausk F, McCutchan A, Spechko P, Schreiber R, Gigli I . Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest. 1986; 78(4):977-82. PMC: 423736. DOI: 10.1172/JCI112688. View

Ehrnst A, Sonnerborg A, Bergdahl S, Strannegard O . Efficient isolation of HIV from plasma during different stages of HIV infection. J Med Virol. 1988; 26(1):23-32. DOI: 10.1002/jmv.1890260105. View

Robinson Jr W, Montefiori D, Gillespie D, MITCHELL W . Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr (1988). 1989; 2(1):33-42. View

Laurence J, Saunders A, Kulkosky J . Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity. Science. 1987; 235(4795):1501-4. DOI: 10.1126/science.2435004. View

10.

Matsuda S, Gidlund M, Chiodi F, Cafaro A, Nygren A, Morein B . Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies in vitro. Scand J Immunol. 1989; 30(4):425-34. DOI: 10.1111/j.1365-3083.1989.tb02446.x. View

11.

Coombs R, Collier A, Allain J, Nikora B, Leuther M, Gjerset G . Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989; 321(24):1626-31. DOI: 10.1056/NEJM198912143212402. View

12.

Cooper N, Nemerow G . Complement and infectious agents: a tale of disguise and deception. Complement Inflamm. 1989; 6(4):249-58. DOI: 10.1159/000463100. View

13.

Ho D, Moudgil T, Alam M . Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989; 321(24):1621-5. DOI: 10.1056/NEJM198912143212401. View

14.

Bolognesi D . AIDS. Do antibodies enhance the infection of cells by HIV?. Nature. 1989; 340(6233):431-2. PMC: 7095050. DOI: 10.1038/340431a0. View

15.

Carini C, Perricone R, Fratazzi C, Fontana L, De Carolis C, DAmelio R . Complement activation is associated with the presence of specific human immunodeficiency virus (HIV)-anti-HIV immune complexes in patients with acquired immunodeficiency syndrome-related complex or lymphoadenopathy syndrome. Scand J Immunol. 1989; 30(3):347-53. DOI: 10.1111/j.1365-3083.1989.tb01220.x. View

16.

. Antibody-dependent enhancement of HIV infection. Lancet. 1988; 1(8597):1285-6. View

17.

Willey R, Smith D, Lasky L, THEODORE T, Earl P, Moss B . In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol. 1988; 62(1):139-47. PMC: 250512. DOI: 10.1128/JVI.62.1.139-147.1988. View

18.

Spear G, Landay A, Sullivan B, Dittel B, Lint T . Activation of complement on the surface of cells infected by human immunodeficiency virus. J Immunol. 1990; 144(4):1490-6. View

19.

Hirsch R . The complement system: its importance in the host response to viral infection. Microbiol Rev. 1982; 46(1):71-85. PMC: 373211. DOI: 10.1128/mr.46.1.71-85.1982. View

20.

Hoshino H, Tanaka H, Miwa M, Okada H . Human T-cell leukaemia virus is not lysed by human serum. Nature. 1984; 310(5975):324-5. DOI: 10.1038/310324a0. View